Xencor (XNCR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual Meeting scheduled for June 16, 2026, at 1:00 p.m. Pacific Time at company headquarters in Pasadena, CA.
Proxy materials are available online, with options to request paper or email copies at no charge.
Stockholders can vote via Internet, mail, telephone, or in person at the meeting.
Voting matters and shareholder proposals
Election of nine directors to serve until the next annual meeting and until successors are elected.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Approval of amendment to the 2023 Equity Incentive Plan to increase authorized shares by 4,000,000.
Advisory (non-binding) vote on executive compensation as disclosed in the proxy statement.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and all proposals.
Nine nominees listed for election, including Dr. Bassil I. Dahiyat and Dr. Raymond J. Deshaies.
Latest events from Xencor
- XmAb942 and XmAb412 advance as next-gen IBD therapies, with pivotal data expected in 2027.XNCR
Digestive Disease Week Conference11 May 2026 - Q1 2026 saw revenue drop, net loss widen, and strong liquidity as clinical milestones approach.XNCR
Q1 20266 May 2026 - Proxy seeks approval for director elections, auditor, equity plan amendment, and executive pay.XNCR
Proxy filing27 Apr 2026 - Advancing bispecific antibody programs in oncology and autoimmune diseases, with pivotal trials ahead.XNCR
Leerink Global Healthcare Conference 202626 Mar 2026 - Lead oncology and immunology assets advance toward pivotal trials and broad commercialization.XNCR
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Pivotal studies and novel biologics in oncology and autoimmune diseases drive clinical momentum.XNCR
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Pipeline progress, improved financials, and extended royalty revenue outlook through 2028.XNCR
Q4 202525 Feb 2026 - Multiple clinical readouts and new trials in autoimmune and oncology set for 2025.XNCR
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Broadened pipeline targets IBD and autoimmune diseases, with pivotal clinical data expected in 2025-2026.XNCR
7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026